HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors.

AbstractPURPOSE:
The usefulness of 2-[(18)F]-fluoro-2-deoxy-D-glucose ([(18)F]FDG) positron emission tomography (PET) can help predict the grade of malignancy and staging in thymic epithelial tumors. However, no satisfactory biologic explanation exists for this phenomenon. The aim of this study was to investigate the underlying biologic mechanisms of [(18)F]FDG uptake.
PATIENTS AND METHODS:
Forty-nine patients with thymic epithelial tumors who underwent [(18)F]FDG PET were included in this study. Tumor sections were stained by immunohistochemistry for glucose transporter 1 (GLUT1), glucose transporter 3 (GLUT3), hypoxia-inducible factor-1 alpha (HIF-1alpha), vascular endothelial growth factor (VEGF), microvessels (CD31 and CD34), cell cycle control marker (p53), and apoptosis marker (bcl-2). We also conducted an in vitro study of [(18)F]FDG uptake in a thymic tumor cell line.
RESULTS:
There was a positive correlation between [(18)F]FDG uptake and GLUT1 (P < .0001), HIF-1alpha (P = .0036), VEGF (P < .0001), microvessel density (MVD; P < .0001), and p53 (P = .0002). GLUT3 and bcl-2 showed no positive correlation with [(18)F]FDG uptake. The expression of Glut1, HIF-1alpha, VEGF, CD31, CD34, and p53 was also significantly associated with the grade of malignancy and poor outcome in thymic epithelial tumors, whereas this relationship was not observed in GLUT3 and bcl-2. Our in vitro study demonstrated that upregulation of GLUT1 and HIF-1alpha was closely associated with [(18)F]FDG uptake into thymic tumor cell.
CONCLUSION:
[(18)F]FDG uptake in thymic epithelial tumors is determined by the presence of glucose metabolism (GLUT1), hypoxia (HIF-1alpha), angiogenesis (VEGF and MVD), and cell cycle regulator (p53).
AuthorsKyoichi Kaira, Masahiro Endo, Masato Abe, Kazuo Nakagawa, Yasuhisa Ohde, Takehiro Okumura, Toshiaki Takahashi, Haruyasu Murakami, Asuka Tsuya, Yukiko Nakamura, Tateaki Naito, Isamu Hayashi, Masakuni Serizawa, Yasuhiro Koh, Hirofumi Hanaoka, Hideyuki Tominaga, Noboru Oriuchi, Haruhiko Kondo, Takashi Nakajima, Nobuyuki Yamamoto
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 28 Issue 23 Pg. 3746-53 (Aug 10 2010) ISSN: 1527-7755 [Electronic] United States
PMID20625125 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma (diagnostic imaging, metabolism, pathology)
  • Female
  • Fluorodeoxyglucose F18 (pharmacokinetics)
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Positron-Emission Tomography
  • Radiopharmaceuticals (pharmacokinetics)
  • Thymus Neoplasms (diagnostic imaging, metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: